Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) EBITDA (2016 - 2025)

Apyx Medical (APYX) has disclosed EBITDA for 15 consecutive years, with $57000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 101.87% year-over-year to $57000.0, compared with a TTM value of -$6.4 million through Dec 2025, up 66.04%, and an annual FY2025 reading of -$6.4 million, up 66.04% over the prior year.
  • EBITDA was $57000.0 for Q4 2025 at Apyx Medical, up from -$832000.0 in the prior quarter.
  • Across five years, EBITDA topped out at $57000.0 in Q4 2025 and bottomed at -$6.6 million in Q1 2024.
  • Average EBITDA over 5 years is -$4.0 million, with a median of -$4.3 million recorded in 2021.
  • The sharpest move saw EBITDA plummeted 349.15% in 2024, then soared 101.87% in 2025.
  • Year by year, EBITDA stood at -$1.7 million in 2021, then tumbled by 250.65% to -$5.9 million in 2022, then grew by 2.65% to -$5.8 million in 2023, then soared by 47.23% to -$3.0 million in 2024, then skyrocketed by 101.87% to $57000.0 in 2025.
  • Business Quant data shows EBITDA for APYX at $57000.0 in Q4 2025, -$832000.0 in Q3 2025, and -$2.6 million in Q2 2025.